Layne Reusser, MD
Cardiovascular Disease · Wichita, KSNPI 1003879974
Payments from drug & device makers
Across 360 payments — averaging $253.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$83K
- Medtronic$3K
- Abbott$2K
- Siemens Medical Solutions USA, Inc.$940
- E.r. Squibb & Sons, L.L.C.$390
- AstraZeneca$345
- plus $2K from 24 others
What the payments were for
- Consulting fees$3000%
- Speaking & faculty fees$79,89087%
- Travel & lodging$4,6655%
- Food & beverage$6,4127%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 82 | $83,147 |
| Medtronic(2 entities) | 80 | $2,821 |
| Abbott | 23 | $2,036 |
| Siemens Medical Solutions USA, Inc. | 6 | $940 |
| E.r. Squibb & Sons, L.L.C. | 87 | $390 |
| AstraZeneca | 15 | $345 |
| Edwards Lifesciences | 1 | $166 |
| Amgen | 11 | $155 |
| Abiomed | 2 | $148 |
| Biotronik Inc. | 3 | $136 |
| Inari Medical, Inc. | 1 | $120 |
| Surmodics, Inc. | 9 | $119 |
| Penumbra, Inc. | 1 | $111 |
| Cvrx, Inc. | 2 | $102 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 5 | $97 |
| Novartis | 5 | $77 |
| Pfizer | 5 | $60 |
| Kestra Medical Technology Services, Inc. | 3 | $58 |
| Boston Scientific | 2 | $57 |
| Sanofi-aventis U.S. LLC | 4 | $47 |
| Bardy Diagnostics, Inc. | 3 | $28 |
| Regeneron Healthcare Solutions, Inc. | 2 | $23 |
| Novo Nordisk | 1 | $21 |
| Canon Medical Systems USA, Inc. | 1 | $20 |
| Heartflow, Inc. | 1 | $18 |
| Gilead | 1 | $16 |
| Merck | 1 | $15 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $13 |
| Boehringer Ingelheim | 1 | $12 |
| Amarin Pharma, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XARELTO$82,388
- Micra$1,296
- AVEIR$1,161
- Artis zee$714
- FLOWTRIEVER CATHETER, S$239
- Edwards SAPIEN 3 Transcatheter Heart Valve$166
- MitraClip System$146
- Xience V coronary stent system$144
- Impella$141
- Xience Sierra Coronary Stent System$138
- SYMPLICITY G3$123
- Indigo System$111
How this compares
$91,311 in reported general payments places this provider in the 90th percentile of 175 cardiovascular disease providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 908 | $748,542 |
| XareltoRivaroxaban | 628 | $588,866 |
| EntrestoSacubitril/Valsartan | 86 | $89,827 |
| MultaqDronedarone Hcl | 41 | $54,403 |
| Repatha SureclickEvolocumab | 42 | $36,655 |
| BrilintaTicagrelor | 54 | $27,161 |
| JardianceEmpagliflozin | 30 | $25,555 |
| Digoxin | 704 | $14,942 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 543 | $13,470 |
| Metoprolol Succinate | 1,266 | $13,263 |
| Nebivolol Hcl | 190 | $11,731 |
| Verapamil ErVerapamil Hcl | 526 | $11,526 |
| Nitroglycerin PatchNitroglycerin | 238 | $9,400 |
| VerquvoVericiguat | 12 | $9,009 |
| Atorvastatin Calcium | 1,052 | $7,815 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $60 | $748,542908 claims |
| Johnson & JohnsonXarelto | $83,147 | $588,866628 claims |
| NovartisEntresto | $77 | $89,82786 claims |
| Sanofi-aventis U.S. LLCMultaq | $47 | $54,40341 claims |
| AstraZenecaBrilinta | $345 | $27,16154 claims |
| Boehringer IngelheimJardiance | $12 | $25,55530 claims |
| MerckVerquvo | $15 | $9,00912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 175 cardiovascular disease providers in Kansas.
Other cardiovascular disease in Wichita
- Bassem ChehabWichita$5.9M
- Wassim ShaheenWichita$1M
- Aziz MaksoudWichita$847K
- Thomas AshcomWichita$193K
- Joseph GalichiaWichita$177K
- Hossein AmiraniWichita$18K
- Ahmed MohamedWichita$17K
- Daniel AlvarezWichita$16K
- Freidy EidWichita$13K
- Mohamad FarhatWichita$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.